| 臺大學術典藏 |
2020-03-06T05:26:31Z |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
|
Wu J.-Y.; Wu S.-G.; Yang C.-H.; Gow C.-H.; YIH-LEONG CHANG; Yu C.-J.; Shin J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:31Z |
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
|
Wu S.-G.; Gow C.-H.; Yu C.-J.; YIH-LEONG CHANG; Yang C.-H.; Hsu Y.-C.; Shih J.-Y.; Lee Y.-C.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:30Z |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
|
Wu S.-G.; YIH-LEONG CHANG; Hsu Y.-C.; Wu J.-Y.; Yang C.-H.; Yu C.-J.; Tsai M.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:25Z |
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
|
Wu S.-G.; Yang C.-H.; Yu C.-J.; Lee J.-H.; Hsu Y.-C.; YIH-LEONG CHANG; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:24Z |
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction
|
Wu S.-G.; YIH-LEONG CHANG; Lin J.-W.; Wu C.-T.; Chen H.-Y.; Tsai M.-F.; Lee Y.-C.; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:22Z |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with Wild-type EGFR
|
Tsai M.-F.; Yu C.-J.; Yang C.-H.; Yang P.-C.; Wu S.-G.; Kuo Y.-W.; YIH-LEONG CHANG; Shih J.-Y.; Chen Y.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:22Z |
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
|
Tsai T.-H.; Wu S.-G.; YIH-LEONG CHANG; Wu C.-T.; Tsai M.-F.; Wei P.-F.; Yang C.-H.; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:21Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai T.-H.; Su K.-Y.; Wu S.-G.; YIH-LEONG CHANG; Luo S.-C.; Jane I.-S.; Yu C.-J.; Yue S.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:19Z |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
|
Wu S.-G.; Hu F.-C.; YIH-LEONG CHANG; Lee Y.-C.; Yu C.-J.; Chang Y.-C.; Wu J.-Y.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:17Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:16Z |
Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: Identification of a rare CD74-NRG1 translocation case
|
Gow C.-H.; Wu S.-G.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:09Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:07Z |
The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition
|
Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:05Z |
Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C
|
Chang T.-H.; Tsai M.-F.; Gow C.-H.; Wu S.-G.; Liu Y.-N.; YIH-LEONG CHANG; Yu S.-L.; Tsai H.-C.; Lin S.-W.; Chen Y.-W.; Kuo P.-Y.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:05Z |
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
|
Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:02Z |
IGFBP7 Drives resistance to epidermal growth factor receptor tyrosine kinase inhibition in lung cancer
|
Wu S.-G.; Chang T.-H.; Tsai M.-F.; Liu Y.-N.; Hsu C.-L.; YIH-LEONG CHANG; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:01Z |
Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer
|
Liu Y.-N.; Tsai M.-F.; Wu S.-G.; Chang T.-H.; Tsai T.-H.; Gow C.-H.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-05T08:04:09Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; MIN-SHU HSIEH; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:08Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:02Z |
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
|
Gow C.-H.;Min-Shu Hsieh;Wu S.-G.;Shih J.-Y.; Gow C.-H.; MIN-SHU HSIEH; Wu S.-G.; Shih J.-Y. |
| 國立成功大學 |
2020 |
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
|
Wu, S.-G.;Chiang, Chiang C.-L.;Liu, C.-Y.;Wang, C.-C.;Su, P.-L.;Hsia, T.-C.;Shih, J.-Y.;Chang, G.-C. |
| 臺大學術典藏 |
2019 |
MicroRNA in lung cancer metastasis
|
Wu S.-G.;Chang T.-H.;Liu Y.-N.;Jin-Yuan Shih; Wu S.-G.; Chang T.-H.; Liu Y.-N.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2018-09-10T15:17:15Z |
Treatment outcome of patients with isoniazid mono-resistant tuberculosis
|
Yu, C. -J.; Wang, J. -Y.; Lee, J. -J.; Chien, J. -Y.;Chen, Y. -T.;Wu, S. -G.;Lee, J. -J.;Wang, J. -Y.;Yu, C. -J.; Chien, J.-Y. and Chen, Y.-T. and Wu, S.-G. and Lee, J.-J. and Wang, J.-Y. and Yu, C.-J.; 余忠仁;吳尚俊;王振源;簡榮彥; Chien, J. -Y.; Chong-Jen Yu; JANN-YUAN WANG; Chen, Y. -T.; Wu, S. -G.; JUNG-YIEN CHIEN |
| 臺大學術典藏 |
2018-09-10T09:13:23Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai, T.-H. and Su, K.-Y. and Wu, S.-G. and Chang, Y.-L. and Luo, S.-C. and Jane, I.-S. and Yu, C.-J. and Yue, S.-L. and Shih, J.-Y. and Yang, P.-C.; Tsai, T-H.;Su, K-Y.;Wu, S-G.;Chang, Y-L.;Luo, S-C.;Jan, I-S.;Yu, C-J.;Yu, S-L.;Shih, J-Y.;Yang, P-C.; 俞松良 ;詹一秀 ;張逸良 ;楊泮池 ;余忠仁 ;吳尚俊 ;蔡子修 ;施金元; Tsai, T-H.; YIH-LEONG CHANG; Tsai, T-H.; Chong-Jen Yu; Su, K-Y.; Wu, S-G.; Wu, S-G.; KANG-YI SU; JIN-YUAN SHIH; Chang, Y-L.; Luo, S-C.; Luo, S-C.; Jan, I-S.; Jan, I-S.; Yu, C-J.; Yu, S-L.; Shih, J-Y.; Shih, J-Y.; Yang, P-C.; 楊泮池 |
